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Abstract
In Spain, the QUANTUM project has been promoted to reduce variability in clinical practice and improve the care and quality 
of life of people with psoriatic arthritis (PsA) by accrediting PsA units throughout the Spanish national health system. To 
present the results of this approach which sought to ensure an optimum level of quality for patients with PsA. Descriptive 
analysis of the self-assessments that the PsA units have carried out assessing their degree of compliance with the quality 
standards established in the QUANTUM project grouped into four blocks: shortening time to diagnosis; optimizing disease 
management; improving multidisciplinary collaboration; and improving patient monitoring. A total of 41 PsA units were 
self-evaluated. They met 64.1% of the defined quality standards. Optimize disease management obtained a higher level of 
standards compliance (72%) and improve multidisciplinary collaboration the lesser (63.9%). Accessibility to the treatments 
available for PsA in all hospitals was guaranteed (100%). Appropriate diagnostic equipment is available (97.6%). Compli-
ance with specific quality standards leads to detect actions that should be implemented: quality of life assessment (9.8%), 
locomotor system assessment (12.2%), physical examination data record (14.6%), periodic cardiovascular risk assessment 
(17.1%). The QUANTUM project results make it possible to visualise how to care for patients with PsA is being developed 
in Spain. Problems identified in recent multinational reports are also identified in Spain.
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Abbreviations
CRP  C-reactive protein
DAPSA  Disease activity in psoriatic arthritis
ESR  Erythrocyte sedimentation rate
EULAR  European league against rheumatism
GRAPPA  Group for Research and Assessment of Psoria-
sis and Psoriatic Arthritis
MDA  Minimal disease activity
MRI  Magnetic resonance imaging
PsA  Psoriatic arthritis
PsAID  Psoriatic arthritis impact of disease
Introduction
Psoriatic arthritis (PsA) is a chronic, progressive, multior-
gan disease [1] common (10–20%) among patients suffering 
from psoriasis. It presents a relapsing course throughout life, 
with periods of inactivity and others of inflammation and 
pain. The EPISER study [2] has established the prevalence 
of PsA in Spain in 0.58% of the population over 18 years 
of age.
GRAPPA (Group for Research and Assessment of Pso-
riasis and Psoriatic Arthritis) [3] has studied worldwide the 
factors that contribute to a decrease in the quality of care 
received by patients diagnosed with PsA. The conclusions 
of this group indicated variable care across health systems, 
which may result in progression of the disease does not stop, 
there is a gradual reduction in function, an increase in dis-
ability and a poor quality of life of the patients. For example, 
in Spain it has been observed that around 60% of the medical 
records did not quantify the joint involvement and in 87% 
there was no composite joint index and 84% did not have a 
measure of function [4, 5].
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The quality standards proposed by the NEXUS project [6] 
or the European League Against Rheumatism (EULAR) [7] 
recommendations have sought to promote integrated care by 
the multidisciplinary teams that intervene in PsA [8, 9], and 
they have been oriented towards improving the quality of 
healthcare received by these patients, establishing a metric 
and recommendations for achieving optimal quality of care.
Among the areas of improvement that cover the different 
stages of PsA, the following have been identified: reducing 
the current delay in diagnosis (this can be up to two years 
on average due, fundamentally, to the lack of awareness of 
the disease and the time available for consultations); achiev-
ing management of the disease by multidisciplinary teams; 
increasing accessibility to the use of biologics in the treat-
ment of PsA; and promoting an adequate management of the 
comorbidities present in patients with PsA.
In Spain, the QUANTUM (quality initiative to improve 
outcomes) project was initiated in 2017 [10]. It has been 
promoted within the framework of QUANTUM interna-
tional and the GRAPPA initiative [3], to adapt to the Span-
ish public health system this set of quality standards that 
seek to reduce variability in clinical practice and improve 
the care and quality of life of people with PsA. To achieve 
this objective, a set of good patient management criteria 
have been elaborated that standardize good organizational, 
diagnostic and therapeutic practices. A total of 15 PsA units 
have participated.
This set of criteria is the result of consensus work with 15 
specialists who agreed on a proposal for quality criteria (who 
worked in different hospitals), some of which were consid-
ered obligatory (18 in total) and, therefore, indispensable for 
achieving quality care.
The QUANTUM project has promoted the accredita-
tion of PsA units throughout Spain. This paper presents the 
results of this exercise which sought to ensure an optimum 
level of quality for patients with PsA.
Method
The evaluations carried out and included in this study were 
based on the quality standards established in the QUAN-
TUM project at the national level [11]. This project defined 
by consensus a set of criteria for optimal quality of care in 
PsA. The criteria consisted of 59 standards (18 mandatory 
and 41 non-mandatory standards), grouped into 4 blocks: 
shortening time to diagnosis (n = 6), optimizing disease 
management (n = 26), improving multidisciplinary collabo-
ration (n = 9), and improving patient monitoring (n = 18). 
The level of compliance required varies between standards, 
in some cases the objective level is dichotomous (yes/no), 
while in others the compliance required ranges from 50 to 
100%, with 80% being the most frequent value. According 
to the QUANTUM project, PsA units must meet more than 
70% of the quality standards (including the 18 mandatory 
ones) to be accredited.
The PsA units that voluntarily participated in this study 
individually carried out a self-evaluation to subsequently 
proceed to the accreditation offered by the QUANTUM 
project. Only aggregated data collected for the accredita-
tion using QUANTUM criteria were used in this study. The 
self-evaluation procedure was supported by an online appli-
cation (https ://apsqu antum .com) that facilitated this evalu-
ation task. Each unit determined the people who were to 
conduct this self-assessment and for each standard they had 
to provide evidence to justify the assessment assigned in 
each standard.
Where individual units did not meet the quality stand-
ards there was the option of drawing up an improvement 
plan, submitting it to external review on a voluntary basis 
and, after implementing the agreed measures, requesting an 
external visit to obtain an opinion on their possible accredi-
tation in accordance with the QUANTUM project standards.
Results
Between July and September 2019, a total of 41 PsA units 
were self-evaluated (7, 17.1% located in county hospitals 
with less than 400 beds and 36, 87.8% in university hospi-
tals). These hospitals belonged to a total of 13 autonomous 
health services.
The PsA units of these hospitals met 64.1% of the 
defined quality standards, 71.5% of the obligatory stand-
ards and 60.9% of the non-compulsory standards. Although 
the average compliance rate was close to the level required 
for accreditation, only two (4.9%) of the participating units 
met the 18 mandatory standards, so the rest would not be 
accredited at that stage. The units contributed improvement 
plans in those cases in which the standard was not satisfied, 
the calendar for the implementation of these plans varying 
around 12 months. Table 1 shows the degree of compliance 
achieved overall by the set of PsA units that carried out the 
self-assessment procedure in each of the blocks. Table 2 
shows the quality standards that the majority of PsA units 
met, along with those in which almost all had problems 
reaching the reference value of the standard.
Most PsA units had access to ultrasound and magnetic 
resonance imaging (40, 97.6%). The centres that had a radi-
ology service that assigned equipment specifically to the 
musculoskeletal system were 37 (90.2%).
The average time of the first consultation and successive 
consultations, of 30 min and 20 min, respectively, recom-
mended in the QUANTUM project quality standards was 
met by 19 (46.3%) units.
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In total, 25 (61%) units had a specific protocol for the 
care of PsA patients. In most units (31, 75.6%) the patient 
was attended by the same rheumatologist in successive 
consultations.
In 12 (29.3%) of the units there was no referral protocol 
from dermatology for suspected PsA. Only 17 (41.5%) of the 
centres held joint clinical sessions between dermatology and 
rheumatology. And only 20 (48.8%) had joint protocols for 
diagnosing and treating PsA.
They reported having a referral in each primary care 
health centre for the pathology of the locomotor system 25 
(61%) units. However, for the most part (39, 95.1%), rota-
tions of family medicine residents in rheumatology services 
were facilitated.
The units with a specific nursing consultation for patients 
with PsA were 35 (85.4%). Patient education information 
was only available in 21 (51.2%) PsA units.
Patient satisfaction was regularly assessed in 17 (41.5%) 
of the self-evaluated units.
Table 1  QUANTUM project. 
Compliance with quality 













Shorten time to diagnosis 6 0 71.5 –
Optimize disease management 26 7 72 71
Improve multidisciplinary collaboration 9 2 63.9 58.5
Improve monitoring 18 9 50.2 74.8
Table 2  QUANTUM project. Standards met (90%) and not met (20%) by most PsA units in each block
Block Standards Compliance (%)
Shorten time to diagnosis Family residents and primary care physicians will be provided with rotations for 
rheumatology services
95.1
Optimize disease management In the pharmacy catalogue of the centre, all the targets authorised for PsA should be 
accessible at all times
100
Centres treating patients with PsA should have access to ultrasound and magnetic 
resonance imaging (MRI)
97.6
The consultation where attention is paid to patients with PsA must have or have 
permanent access to computer/scale and microscope
95.1
Services should participate in and develop exclusive PsA training activities and 
continuing education programmes in PsA
92.7
Outpatient consultations where PsA patients are cared for should be accessible and 
signalled
92.7
The radiology service of the hospitals where patients with PsA are treated should 
have a team specifically dedicated to the locomotor system
90.2
Improve multidisciplinary collaboration The existence of a vaccination protocol in the service and the referral circuit with 
preventive medicine should be evaluated to update the vaccination calendar in 
patients with PsA
92.7
Improve monitoring It should be performed as complementary tests to the patient with PsA, at least in the 
two consecutive visits of 6 months or more, hemogram and general biochemistry
97.6
The value of the C-reactive protein (CRP) in two consecutive visits of 6 months or 
more and of the erythrocyte sedimentation rate (ESR) on an annual basis should be 
recorded in patients with PsA
95.1
In PsA patients, the evaluation of their quality of life with the Psoriatic Arthritis 
Impact of Disease (PsAID) index should be carried out at least once a year
9.8
In the clinical history of patients with psoriasis of the dermatology service, it should 
be noted that specific questions about the locomotor system have been asked at 
least once a year
12.2
In the clinical history of a patient with PsA, at least one general physical examina-
tion containing auscultation, abdominal perimeter, weight and height should be 
collected annually
14.6





Most of the units (36, 87.8%) had participated in at least 
one clinical trial in the last 5 years and 16 (39%) held at least 
3 clinical sessions per year.
Table 3 shows the result of the internal audits of clinical 
records foreseen in the QUANTUM project.
Table 4 shows an example of an improvement plan. The 
improvement plans contributed by the units were articulated 
in the following points: quality standard to which reference 
was made, the definition of the problem identified, descrip-
tion of the causes that cause it, what effect it causes, what 
activities are planned to be implemented to solve this prob-
lem, specification of who should supervise this implementa-
tion and when, and specification of what results are expected 
to be obtained to determine whether the problem has been 
resolved.
Discussion
The QUANTUM project results make it possible to visualise 
how to care for patients with PsA is being delivered in Spain, 
both in terms of resources and the care process.
To our knowledge, this is the first initiative aimed at the 
accreditation of specialized units in PsA. No equivalent pro-
posals have been identified in other countries and, at the 
moment, we do not know of any health system outside Spain 
that has adapted the QUANTUM project. The initiatives 
developed to date have focused on some specific aspects to 
improve the quality of care for patients with PsA. Examples 
of these improvements include assuring multidisciplinary 
care [12], the incorporation of patient-reported outcome 
measures (GRAPPA-OMERACT) [13, 14], introducing 
structural, process and outcome indicators [6], progress 
in biological treatments and the evaluation of their results 
(MERECES study) [15, 16]. However, no approach has been 
identified that focuses on the clinical management of the 
PsA units, ensuring the cycle of improvement in both care 
quality and patient safety. The QUANTUM project consid-
ers the PsA unit as a whole, with all the aspects that must be 
considered in the management of this type of unit, including 
integrated care, specialized training, systematic recording of 
data in the clinical history, screening, diagnosis, treatment, 
and evaluation of clinical results [10]. From this perspec-
tive, special attention is paid to the necessary collaboration 
between professionals and specialties involved in the man-
agement of patients with PsA (primary care, rheumatology, 
dermatology and nursing) [17] and the incorporation of 
validated clinical and psychosocial measures [13, 14, 16].
The data provided in the analysis of the result of the 
self-assessments show that some of the problems identified 
in recent multinational reports [4, 7] are also identified in 
Spain. In view of these results, care integrated by interdisci-
plinary teams has not been implemented, the implementation 
of practice guidelines requires greater effort and monitoring 
of patients over time is highly variable. The care of patients 
Table 3  QUANTUM project. Results of the review of medical records to verify compliance with quality standards (N = 41)
Only the number of units that met the quality standard is reflected in the table
Standard Compliance N (%) Average (SD) C.I for the mean 
(95%)
Lower lim Upper lim
The patient’s medical history must include the date of joint diagnosis, the onset of 
psoriasis symptoms, and the specific form of involvement of that patient (periph-
eral, axial, mixed, etc.)
21 (51.2) 76.2 (15.4) 71.5 80.9
In the clinical history of a patient with PsA at least one general physical examina-
tion containing auscultation, abdominal perimeter, weight and height should be 
collected annually
6 (14.6) 48.5 (25.4) 40.8 56.2
In patients with peripheral PsA the Minimal Disease Activity (MDA), Disease 
Activity in Psoriatic Arthritis (DAPSA) or any other validated global activity 
index should be used, recording all the sections that make up this index on an 
annual basis in the clinical history
28 (68.3) 54.2 (28.3) 45.6 62.8
Annually, a lipidic profile and uricemia should be performed on the patient with PsA 33 (80.5) 88.8 (15.3) 84.2 93.4
In patients with PsA a specific cardiovascular risk assessment should be performed 
at least every 2 years
7 (17.1) 37.6 (31.7) 28.0 47.1
In patients with PsA X-rays of hands/feet, pelvis, chest, and symptomatic joints 
should be performed and included
27 (65.9) 80.1 (16.6) 75.0 85.1
In patients with PsA with peripheral involvement, X-rays of affected joints should be 
performed with a minimum periodicity of 3 years
12 (29.3) 68.1 (23.1) 61.1 75.1
In patients with PsA the evaluation of disease with the PsAID index should be car-
ried out with a minimum annual periodicity
4 (9.8) 17.2 (25.4) 9.6 24.9
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within the framework of a joint face-to-face model [11] is 
not implemented in all the self-evaluated units.
The supervision of the course of the patients and the coor-
dination between dermatology and rheumatology derived 
from these evaluations confirm the trend in the improvement 
of multidisciplinary care observed in some of the studies [8].
There is a high accessibility to the treatments available 
for PsA in all hospitals. The training of future professionals 
is fully implemented, including that of primary care doctors, 
through the resident rotation system. Sufficient and appropri-
ate diagnostic equipment is available. The implementation 
of electronic medical records contributes to the unification 
of the data recording system and patient safety. These results 
suggest that some of the barriers identified in other studies 
(such as barriers to care for the co-morbidity suffered by 
these patients or difficulties in identifying patients suffer-
ing from PsA among non-rheumatologists) could have been 
reduced in those centres that meet the QUANTUM project 
quality standards, in line with the idea that reflection on 
organisational aspects, multidisciplinary teamwork or sen-
sitisation of other professionals on PsA through self-evalu-
ation contributes to the improvement of the care received by 
these patients [11].
Indirectly, this study reaffirms the relevance of the 
standards included in the QUANTUM project and allows 
for the corroboration of their usefulness in describing the 
operation of the PsA units and promoting the achievement 
of adequate levels of care quality. Self-assessment based 
on the standards of these quality regulations allows cent-
ers to identify their strengths and weaknesses, as well as 
opportunities for improvement [10].
When interpreting these data, it must be considered 
that they are the result of self-evaluations of PsA units 
and, therefore, correspond to centres that have taken a 
step forward in the organisation of care for this patient 
profile. Although PsA units are located in centres distrib-
uted throughout the entire country and are located in both 
university and county hospitals of different sizes. It must 
also be considered that the selection of these units has not 
been random.
PsA units from 13 of the 17 health services in Spain par-
ticipated in this study. The 41 units involved in the study 
represent those that have considered to best meet the accred-
itation criteria of the total number of units currently in oper-
ation in Spain. It is expected that the remaining units will 
join the project and the accreditation process in the medium 
Table 4  Example of an improvement plan
Standard Improvement plan (example)
In PsA patients, the evaluation of their quality of life with the PsAID 
index will be carried out with a minimum annual periodicity
What is the problem?
In PsA patients the success of the therapy is marked by the disease 
activity of the pathology, so the assessment of the quality of life will 
be a great guidance at the time of decision making
Why does it happen?
In the absence of a protocol that defines what information should be 
contained in the medical history of patients with PsA, it is up to the 
physician to decide
Why address it?
The communication between professionals of this or different levels of 
care will increase the quality of care. The PsAID scale (Gossec et al., 
a patient-derived and patient-reported outcome measure for assessing 
psoriatic arthritis: elaboration and preliminary validation of the Psori-
atic Arthritis Impact of Disease (PsAID) questionnaire, a 13 country 
EULAR initiative. Ann Rheum Dis. 2014; 73: 1012–19) developed by 
EULAR incorporates more elements, including the emotional distress, 
to take into account the appropriate time for the assessment of pain 
and the impact of the disease on quality of life. It will make it possible 
to identify areas that should be addressed in the clinical management 
of the patient and in the control of longitudinal form
How do we solve it?
A protocol of compliance with the PsAID index should be established 
with a minimum annual periodicity, where a value less than 4 is con-
sidered an acceptable patient status; or a change in relation to the last 
application of three points is considered an absolute relevant change
Who will do it and when?
It must be performed by the family doctor or rheumatology specialist at 
the time of the consultation
What results do we intend to achieve?
Implementation is expected in the first year for 45% of patients, in a 
second year for 65% and in the third year for 85% of patients
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term. For this purpose, the Spanish Society for Quality Care 
(Sociedad Española de Calidad Asistencial, SECA) has com-
mitted to disseminate the quality standards in the manage-
ment of PsA and to conduct a face-to-face audit to verify the 
degree of compliance with these standards in the hospitals 
that join the QUANTUM project.
The dynamics of accreditation proposed by the QUAN-
TUM project requires the incorporation of improvements in 
organizations, procedures and results. The 41 participating 
units are immersed in this task. Each of them has received 
an individualized report where they identify the improve-
ment actions to be carried out. The QUANTUM project is 
based on the methodology of the quality assurance cycle. In 
Europe, the total annual cost of psoriatic arthritis per patient 
ranges from US$ 10,924 to US$ 17,050 [18]. Compliance 
with QUANTUM regulations is expected to lead to a reduc-
tion in costs by reducing or eliminating non-quality costs 
[10].
The main limitation is that the self-assessment process 
often differs from the accreditation process, and there is less 
compliance than has been stated. On the other hand, some 
criteria depend on the rheumatology service, but there are 
some more general criteria of the centers.
Conclusions
Standards of care for patients with PsA are variable. The 
QUANTUM project aims to improve these standards through 
benchmarking. This is the first report of a national endeavour 
to audit current practice against the existing standards with 
a view to changing practice, thus completing the audit cycle 
and improving compliance.
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